Clinical Trial Update: Empaglifozin in Early Diabetic Kidney Disease [Phase 3]

View source ↗

Summary

Phase 3 trial of empagliflozin in early diabetic kidney disease was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Kidney Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Conditions: Diabetic Kidney Disease, Diabetes Mellitus Type 2 | Phase 3 | Status: WITHDRAWN